课题基金 / 基金详情

The SCF(FBXO11) - XAB2 axis mediates DNA repair and therapeutic resistance in small cell lung cancer

The SCF(FBXO11) - XAB2 axis mediates DNA repair and therapeutic resistance in small cell lung cancer
SCF(FBXO11) - XAB2 轴介导小细胞肺癌的 DNA 修复和治疗耐药
批准号：
409474
负责人：
Lok Benjamin
金额：
$71.72万
依托单位：
University Health Network (Toronto)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-09-01 至 2024-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=409474&lang=en
关键词：
Cisplatin Crispr Genetic Screen Dna Repair Homologous Recombination Lung Cancer Parp Inhibitor Patient-Derived Xenografts Small Cell Lung Cancer Treatment Resistance Ubiquitin-Proteasome Pathway

项目摘要

项目成果

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In Canada, lung cancer is responsible for more deaths than colon, breast, and prostate cancer combined. Small cell lung cancer (SCLC) is a particularly aggressive subtype that represents approximately 15% of all lung cancers. Despite an initial response o
期刊论文(0)
专著(0)
科研奖励(0)
会议论文